title: The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir.
abstract: In order to determine prognostic factors associated with treatment failure (TF) in advanced HIV-infected patients treated with a regimen including indinavir, a prospective cohort study of 80 patients was set up between 1 March and 31 December 1996. TF time was calculated using the Kaplan-Meier method, from treatment induction to the first of the following events: treatment modification for adverse event or lack of significant virological and/or immunological response, AIDS-defining diagnosis or death. Date of point was 31 December 1998. Multivariate analysis was performed using a Cox model. At baseline, 60% of the patients were AIDS-free, median viral load and CD4+ count were respectively 4.8 log/ml and 79/microl. After a median follow-up of 26 months, 70% of the patients experienced a TF in a median time of 8 months. Seventy-two per cent presented an hyperbilirubinaemia (>2 mg/dl). In multivariate analysis, initial AIDS stage (hazard ratios [HR]=1.94, P=0.04) and digestive intolerance (HR=2.32, P=0.003) were predictive of TF. Conversely, hyperbilirubinaemia was associated with a better outcome (HR=0.35, P<0.0001). These 2 latter parameters very likely reflected patients' treatment compliance.
authors.affiliation: Saint André University Hospital, Bordeaux, France.
authors.forename: C
authors.initials: C
authors.lastname: Nouts
authors.forename: M
authors.initials: M
authors.lastname: Bonarek
authors.forename: P
authors.initials: P
authors.lastname: Morlat
authors.forename: I
authors.initials: I
authors.lastname: Delevaux
authors.forename: F
authors.initials: F
authors.lastname: Bonnet
authors.forename: D
authors.initials: D
authors.lastname: Lacoste
authors.forename: N
authors.initials: N
authors.lastname: Bernard
authors.forename: J
authors.initials: J
authors.lastname: Beylot
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced*; D019469:Indinavir / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011379:Prognosis; D017211:Treatment Failure
chemical_list: D015415:Biomarkers; D017320:HIV Protease Inhibitors; D019469:Indinavir